drugset / Trial / NCT03621982
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.
Timeline
- Start
- 2018-11-09
- Primary completion
- 2022-12-14
- Completion
- 2022-12-14
Outcome
Outcome not reported
Stopped: “Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity. However, the signals were insufficiently compelling at the tested dose/schedule to justify continuation of the study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ADCT-301 | Monoclonal antibody | 20 ug/kg | Intravenous |
| Subject | ADCT-301 | Monoclonal antibody | 30 ug/kg | Intravenous |
| Subject | ADCT-301 | Monoclonal antibody | 150 ug/kg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |